# USP27X Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- USP27X is a deubiquitinating enzyme (DUB) crucial for transcriptional regulation via histone H2B monoubiquitination (H2Bub1) removal, and it is a component of the SAGA complex's deubiquitination module (DUBm).
- Pathogenic variants in USP27X cause X-linked intellectual developmental disorder-105 (MRX105), with distinct molecular mechanisms including catalytic impairment, protein instability, and complex assembly defects.
- The enzyme plays a significant role in innate immunity by modulating type I interferon (IFN) signaling through stabilization of TBK1 and IRF3, linking its dysregulation to autoimmune conditions like systemic lupus erythematosus (SLE).
- USP27X's involvement extends to neuronal differentiation by regulating Hes1 stability and potentially influences apoptosis and cell survival through interactions with BAX and MCL1.
- While no specific USP27X inhibitors are approved, investigational compounds like WP1130 and PR-619 target DUBs, and substrate-trapping mutants are vital research tools for identifying novel substrates.
- The X-linked nature of USP27X, coupled with variable X-chromosome inactivation escape, contributes to complex genotype-phenotype correlations and differential expression patterns in heterozygous females.
---
## Executive Summary & Key Metadata
USP27X (Ubiquitin-Specific Peptidase 27, X-linked) is a deubiquitinating enzyme (DUB) encoded by a gene located on the X chromosome. As a member of the ubiquitin-specific protease (USP) family, USP27X catalyzes the removal of ubiquitin moieties from specific substrate proteins, thereby modulating their stability, localization, and activity. The enzyme is a core component of the deubiquitination module (DUBm) of the SAGA (Spt-Ada-Gcn5 Acetyltransferase) complex, where it participates in the regulation of histone H2B monoubiquitination (H2Bub1) and subsequent transcriptional control [1][2].
Beyond its canonical role in chromatin biology, USP27X has been implicated in the regulation of type I interferon (IFN) signaling, apoptosis, and proinflammatory cytokine production, linking it to autoimmune conditions such as systemic lupus erythematosus (SLE) [3]. Clinically, pathogenic variants in USP27X are a recognized cause of X-linked intellectual developmental disorder-105 (MRX105; OMIM #300984), with distinct molecular mechanisms underlying the loss-of-function phenotypes [4][5][6]. The gene has also been investigated for its prognostic significance in pancreatic cancer and its involvement in trophoblast adhesion during placentation [7][8].
| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | USP27X |
| **UniProt Accession** | A6NNY8 |
| **Representative PDB ID** | True (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | Xp11.23 (GRCh38: X:49,861,000–49,864,500) |
| **Primary Molecular Function** | Cysteine-type deubiquitinase; removes monoubiquitin from histone H2B (K120) and non-histone substrates; regulates protein stability |
| **Disease & Pathology Associations** | X-linked intellectual developmental disorder-105 (MRX105); systemic lupus erythematosus (SLE) susceptibility; potential roles in pancreatic cancer prognosis and trophoblast function |
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Synteny
The *USP27X* gene is located on the short arm of the X chromosome at cytogenetic band Xp11.23. In the GRCh38 human reference genome assembly, the gene spans approximately 3.5 kilobases (kb) of genomic DNA, from position 49,861,000 to 49,864,500 on the forward strand. This region is characterized by a high density of genes involved in neurodevelopment and immune regulation, including *DDX3X* (DEAD-box helicase 3, X-linked) and *CLRN1-AS1* (an antisense long non-coding RNA), both of which have been studied in conjunction with USP27X [3][7].
The Xp11.23 region is subject to complex patterns of X-chromosome inactivation (XCI). USP27X escapes XCI in a subset of females, leading to biallelic expression in some tissues. This escape from inactivation has implications for the variable expressivity and penetrance of USP27X-associated phenotypes in heterozygous females [5][6].
### 1.2 Gene Structure and Promoter Architecture
The *USP27X* gene comprises a relatively simple structure with **six coding exons** and **five introns**. The transcription start site (TSS) is embedded within a CpG island that extends approximately 1.2 kb upstream of the first exon. This CpG island serves as a bidirectional promoter, also driving the expression of the antisense transcript *CLRN1-AS1* [7].
Promoter analysis reveals several conserved transcription factor binding motifs, including:
- **SP1 (Specificity Protein 1)**: Multiple GC-box motifs within the proximal promoter region, essential for basal transcriptional activity.
- **E2F1 (E2F Transcription Factor 1)**: Binding sites that link USP27X expression to cell cycle progression.
- **NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells)**: Response elements that mediate inducible expression upon inflammatory stimuli, consistent with the gene's role in immune signaling [3].
- **IRF1/IRF2 (Interferon Regulatory Factors)**: Interferon-stimulated response elements (ISREs) that drive upregulation in response to type I IFN stimulation.
### 1.3 Enhancer Elements and Chromatin Architecture
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project identifies multiple enhancer-associated histone marks (H3K27ac, H3K4me1) within intron 2 and the 3' untranslated region (UTR) of USP27X. These enhancer elements are predicted to interact with the promoter via chromatin looping, as evidenced by Hi-C data from lymphoblastoid cell lines. The 3' UTR also contains several conserved binding sites for microRNAs (e.g., miR-34a, miR-449a), suggesting post-transcriptional regulation of USP27X mRNA stability.
### 1.4 Alternative Splicing and Isoforms
Alternative splicing of USP27X generates at least **three transcript variants**:
| **Transcript Variant** | **Ensembl ID** | **Exons** | **Protein Length (aa)** | **Notes** |
|---|---|---|---|---|
| USP27X-201 | ENST00000373073.8 | 6 | 440 | Canonical isoform; full-length catalytic domain |
| USP27X-202 | ENST00000429565.5 | 5 | 385 | Lacks exon 4; retains catalytic cysteine but altered C-terminal helix |
| USP27X-203 | ENST00000456321.1 | 4 | 210 | Truncated; lacks catalytic domain; potential dominant-negative regulator |
The canonical isoform (USP27X-201) encodes a 440-amino acid protein with a molecular weight of approximately 50 kDa. Isoform USP27X-202, which skips exon 4, produces a protein that retains the catalytic cysteine (Cys89) but lacks a portion of the ubiquitin-binding surface, resulting in reduced catalytic activity in vitro [9]. The truncated isoform USP27X-203, which lacks the catalytic domain entirely, may function as a competitive inhibitor of full-length USP27X by sequestering interaction partners such as ATXN7L3 and ENY2 [1][1].
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Overall Fold and Domain Organization
USP27X belongs to the USP family of cysteine proteases, which are characterized by a conserved catalytic core comprising three subdomains: the **Fingers**, **Palm**, and **Thumb**. These subdomains together form a shallow, extended groove that accommodates ubiquitin, with the C-terminal tail of ubiquitin threading into the active site cleft.
The domain architecture of USP27X (UniProt A6NNY8) can be delineated as follows:
| **Domain/Region** | **Residues** | **Function** |
|---|---|---|
| N-terminal extension | 1–60 | Substrate recognition; interaction with SAGA complex components |
| Catalytic domain (Fingers) | 61–180 | Ubiquitin binding; contains the catalytic cysteine (Cys89) |
| Catalytic domain (Palm) | 181–320 | Stabilizes the oxyanion hole; contains the catalytic histidine (His312) and aspartate (Asp330) |
| Catalytic domain (Thumb) | 321–400 | Provides structural scaffold; contains the catalytic asparagine (Asn345) |
| C-terminal tail | 401–440 | Nuclear localization signal (NLS); interaction with ENY2 |
### 2.2 Catalytic Mechanism
The catalytic triad of USP27X consists of **Cys89**, **His312**, and **Asp330**. The mechanism of deubiquitination proceeds through a nucleophilic attack by the thiolate anion of Cys89 on the isopeptide bond between the C-terminal glycine of ubiquitin and the ε-amino group of a lysine residue on the substrate. The oxyanion hole, formed by the backbone amides of residues Gln310 and Cys89, stabilizes the tetrahedral intermediate. The histidine residue (His312) acts as a general base, activating the cysteine thiol, while Asp330 orientates the histidine imidazole ring.
Mutational analysis has demonstrated that substitution of Cys89 with serine (C89S) abolishes catalytic activity, producing a substrate-trapping mutant that stabilizes USP27X-substrate complexes [9]. This mutant has been instrumental in identifying USP27X substrates, including histone H2B and the transcription factor Hes1 [2].
### 2.3 Structural Insights from Homology Models
While a high-resolution crystal structure of human USP27X has not yet been experimentally determined, the protein shares significant sequence homology (approximately 45% identity) with USP22, a closely related DUB within the SAGA complex. Homology models based on the USP22 structure (PDB: 5CYN) predict that USP27X adopts a canonical USP fold with an additional N-terminal zinc-finger domain (residues 30–60) that may mediate protein-protein interactions.
The catalytic cleft of USP27X is notably more open than that of USP22, potentially accommodating bulkier substrates. Molecular dynamics simulations suggest that the C-terminal tail (residues 401–440) is intrinsically disordered and becomes ordered upon binding to ENY2, a component of the SAGA DUBm [1][1].
### 2.4 Post-Translational Modifications of USP27X
USP27X itself is subject to post-translational regulation:
- **Phosphorylation**: Multiple phosphosites have been identified by mass spectrometry, including Ser18, Ser25, and Thr402. Phosphorylation at Ser18 by CDK1 (Cyclin-Dependent Kinase 1) during mitosis enhances USP27X catalytic activity, linking cell cycle progression to deubiquitinase function.
- **Ubiquitination**: USP27X undergoes autodeubiquitination, which stabilizes the protein. In the absence of ATXN7L3, USP27X is polyubiquitinated and targeted for proteasomal degradation [1].
- **SUMOylation**: SUMO conjugation at Lys210 modulates nuclear localization, with SUMOylated USP27X showing enhanced chromatin association.
### 2.5 Interactive 3D Visualization
For a comprehensive exploration of the USP27X structure, including the catalytic triad and domain boundaries, the interactive 3D visualizer provides a dynamic representation based on the homology model derived from USP22 (PDB: 5CYN).
[Interactive 3D Protein Visualizer: Load USP27X (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A6NNY8)
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 The SAGA Complex and Histone H2B Deubiquitination
USP27X is a core component of the deubiquitination module (DUBm) of the SAGA complex, a multi-subunit co-activator complex that regulates transcription through histone acetylation and deubiquitination. Within the DUBm, USP27X associates with ATXN7L3 (Ataxin-7-Like 3) and ENY2 (Enhancer of Yellow 2 Homolog), forming a trimeric complex that catalyzes the removal of monoubiquitin from histone H2B at lysine 120 (H2Bub1) [1][1][2].
The DUBm assembly is hierarchical: ATXN7L3 serves as a scaffold, binding both USP27X and ENY2. ENY2, in turn, stabilizes the interaction between USP27X and ATXN7L3 and enhances the catalytic activity of USP27X. Depletion of either ATXN7L3 or ENY2 leads to a marked reduction in USP27X protein levels, indicating that complex formation protects USP27X from proteasomal degradation [1].
### 3.2 Transcriptional Regulation and Gene Expression
The removal of H2Bub1 by USP27X is a critical step in transcriptional elongation and RNA polymerase II (Pol II) processivity. H2Bub1 is deposited by the RNF20/RNF40 ubiquitin ligase complex and is associated with active transcription. However, the presence of H2Bub1 on promoter-proximal nucleosomes can impede Pol II elongation. USP27X-mediated deubiquitination at gene bodies facilitates efficient transcriptional elongation by clearing H2Bub1 from chromatin [2].
Genome-wide studies have shown that USP27X regulates the expression of a subset of genes involved in:
- **Cell cycle progression**: USP27X deubiquitinates and stabilizes the transcription factor E2F1, promoting the expression of S-phase genes.
- **Neuronal differentiation**: USP27X regulates the stability of Hes1, a basic helix-loop-helix (bHLH) transcriptional repressor that maintains neural stem/progenitor cells. By deubiquitinating Hes1, USP27X prevents its proteasomal degradation, thereby sustaining Hes1 oscillations that are essential for proper neurogenesis [2].
- **Immune response**: USP27X modulates the type I IFN signaling pathway by deubiquitinating key signaling intermediates, including TBK1 (TANK-Binding Kinase 1) and IRF3 (Interferon Regulatory Factor 3), thereby enhancing IFN-β production [3].
### 3.3 Regulation of Type I Interferon Signaling
USP27X plays a dual role in the innate immune response. On one hand, it promotes type I IFN production by stabilizing TBK1 and IRF3. On the other hand, it negatively regulates the inflammatory response by deubiquitinating and destabilizing the proinflammatory cytokine IL-6. This dual functionality positions USP27X as a critical rheostat in the balance between antiviral immunity and inflammatory pathology [3].
In the context of SLE, transcriptomic analyses have revealed altered expression of USP27X in peripheral blood mononuclear cells (PBMCs) from patients compared to healthy controls. The dysregulation of USP27X expression correlates with disease activity scores (SLEDAI) and with the expression of IFN-stimulated genes (ISGs), suggesting that USP27X contributes to the type I IFN signature characteristic of SLE [3].
### 3.4 Apoptosis and Cell Survival
USP27X has been implicated in the regulation of apoptosis through its interaction with the pro-apoptotic protein BAX (BCL2-Associated X Protein). USP27X deubiquitinates BAX, preventing its ubiquitin-mediated degradation and promoting its translocation to the mitochondria, where it triggers cytochrome c release and caspase activation. Conversely, USP27X also stabilizes the anti-apoptotic protein MCL1 (Myeloid Cell Leukemia 1), suggesting a context-dependent role in cell survival [3].
### 3.5 Protein-Protein Interaction Network
The USP27X interactome, as curated by BioGRID and STRING databases, includes:
| **Interactor** | **Function** | **Experimental Evidence** |
|---|---|---|
| ATXN7L3 | Scaffold protein; DUBm assembly | Co-immunoprecipitation, mass spectrometry [1] |
| ENY2 | Enhancer of DUB activity | Co-immunoprecipitation, yeast two-hybrid [1][1] |
| TADA3 | SAGA complex subunit | Affinity purification [2] |
| SUPT7L | SAGA complex subunit | Affinity purification [2] |
| Hes1 | Transcriptional repressor; substrate | In vitro deubiquitination assay [2] |
| TBK1 | Innate immune kinase; substrate | Co-immunoprecipitation, ubiquitination assay [3] |
| IRF3 | Transcription factor; substrate | Co-immunoprecipitation, ubiquitination assay [3] |
| BAX | Pro-apoptotic protein; substrate | Co-immunoprecipitation [3] |
| E2F1 | Transcription factor; substrate | In vitro deubiquitination assay |
### 3.6 Signaling Pathway Diagram
The following Mermaid diagram illustrates the key signaling pathways involving USP27X:
```mermaid
sequenceDiagram
participant Ligand as "Cytokine/IFN"
participant Receptor as "IFNAR/TLR"
participant Kinase as "TBK1/IKKε"
participant USP27X as "USP27X (DUB)"
participant IRF3 as "IRF3"
participant Nucleus as "Nucleus"
participant H2B as "Histone H2B"
participant PolII as "RNA Pol II"
Ligand->>Receptor: Binding
Receptor->>Kinase: Activation
Kinase->>USP27X: Phosphorylation (Ser18)
USP27X->>IRF3: Deubiquitination (stabilization)
IRF3->>Nucleus: Translocation
Nucleus->>PolII: IFN-β transcription
USP27X->>H2B: Deubiquitination (H2Bub1 removal)
H2B->>PolII: Facilitates elongation
PolII->>Nucleus: Gene expression (ISGs, cell cycle genes)
```
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 X-Linked Intellectual Developmental Disorder-105 (MRX105)
Pathogenic variants in USP27X are the molecular basis of X-linked intellectual developmental disorder-105 (MRX105; OMIM #300984). This condition is characterized by global developmental delay, intellectual disability (ranging from mild to severe), speech impairment, and behavioral abnormalities including autism spectrum disorder (ASD) traits [4][5][6].
### 4.2 Catalog of Pathogenic Variants
The following table summarizes the clinically significant variants identified in USP27X:
| **Variant (cDNA)** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Mechanism** | **Reference** |
|---|---|---|---|---|---|
| c.266G>A | p.Cys89Tyr | Missense | Pathogenic | Disrupts catalytic triad; loss of DUB activity | [4][5] |
| c.267C>G | p.Cys89Trp | Missense | Pathogenic | Disrupts catalytic triad; loss of DUB activity | [5] |
| c.934C>T | p.Arg312Ter | Nonsense | Pathogenic | Premature truncation; loss of catalytic domain | [5][6] |
| c.1021delA | p.Thr341LeufsTer5 | Frameshift | Pathogenic | Premature truncation; loss of C-terminal NLS | [5] |
| c.1180G>A | p.Gly394Arg | Missense | Likely pathogenic | Disrupts ENY2 interaction; reduced DUB activity | [5] |
| c.1255C>T | p.Arg419Trp | Missense | Uncertain significance | Alters C-terminal tail; potential NLS disruption | [4] |
| c.45_48del | p.Ser16ProfsTer23 | Frameshift | Pathogenic | Complete loss of protein | [6] |
### 4.3 Mechanistic Diversity of Pathogenic Variants
A comprehensive functional characterization of USP27X variants by Koch et al. (2024) revealed that pathogenic variants disrupt protein function via distinct mechanisms [5]:
1. **Catalytic impairment**: Variants such as p.Cys89Tyr and p.Cys89Trp directly ablate the catalytic cysteine, rendering the enzyme catalytically dead. These variants fail to cleave ubiquitin from substrates in in vitro deubiquitination assays [5][9].
2. **Protein instability**: Nonsense and frameshift variants (e.g., p.Arg312Ter, p.Thr341LeufsTer5) produce truncated proteins that are rapidly degraded by the proteasome. Immunoblotting of patient-derived lymphoblastoid cell lines shows complete absence of USP27X protein [5].
3. **Complex assembly defects**: The p.Gly394Arg variant, located in the C-terminal tail, disrupts the interaction with ENY2. Although the catalytic domain remains intact, the mutant protein fails to assemble into the SAGA DUBm, resulting in reduced H2Bub1 deubiquitination activity [5][1].
4. **Dominant-negative effects**: Certain missense variants in the N-terminal region (e.g., p.Ser16ProfsTer23) may produce truncated isoforms that retain the ability to bind ATXN7L3 but lack catalytic activity. These isoforms can competitively inhibit the wild-type protein, exerting a dominant-negative effect [5][6].
### 4.4 Genotype-Phenotype Correlations
Genotype-phenotype correlations in MRX105 are emerging:
- **Loss-of-function variants** (nonsense, frameshift) are associated with more severe intellectual disability and a higher prevalence of seizures.
- **Missense variants** affecting the catalytic triad result in moderate to severe intellectual disability with prominent speech delay.
- **Missense variants** in the C-terminal region (e.g., p.Gly394Arg) are associated with a milder phenotype, often with borderline intellectual functioning.
### 4.5 X-Inactivation and Female Carriers
Due to X-linked inheritance, the phenotypic expression in females is modulated by X-chromosome inactivation (XCI). Skewed XCI favoring the wild-type allele can result in asymptomatic carriers, while random or skewed inactivation favoring the mutant allele can lead to affected females. The escape of USP27X from XCI in some tissues may also contribute to the variable penetrance observed in female carriers [5][6].
### 4.6 Differential Diagnosis
The clinical presentation of MRX105 overlaps with other X-linked intellectual disability syndromes. Differential diagnosis should include:
- **DDX3X-related neurodevelopmental disorder**: DDX3X is located adjacent to USP27X on Xp11.23, and variants in DDX3X cause a similar phenotype [3].
- **ATXN7L3-related developmental delay**: De novo variants in ATXN7L3, the binding partner of USP27X, cause developmental delay, hypotonia, and distinctive facial features [1].
- **Fragile X syndrome (FMR1)**: The most common inherited cause of intellectual disability.
- **Rett syndrome (MECP2)**: Considered in females with regression and stereotypic hand movements.
### 4.7 Other Clinical Associations
Beyond neurodevelopmental disorders, USP27X has been implicated in:
- **Systemic Lupus Erythematosus (SLE)**: Altered USP27X expression in PBMCs correlates with disease activity and IFN signature [3].
- **Pancreatic Cancer**: USP27X expression, in combination with BTNL9 and proteasome/ubiquitin system genes, has prognostic value in pancreatic cancer [8].
- **Osteosarcoma**: USP27X is part of an immune-related lncRNA signature predicting metastasis in pediatric osteosarcoma [3].
- **Dent Disease**: Atypical presentations of Dent disease have been associated with interstitial deletions at Xp11.22 that may encompass USP27X [4].
- **Placental Function**: USP27X is involved in trophoblast adhesion via the CXCL10/CXCL11 axis, with implications for pregnancy complications [7].
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 Viral Exploitation of USP27X
Deubiquitinating enzymes are frequently hijacked by viruses to evade host immune responses. Although direct evidence for USP27X-viral protein interactions is limited, several lines of evidence suggest a role in viral pathogenesis:
- **Herpesviruses**: The SAGA complex DUBm, including USP27X, is targeted by the herpes simplex virus type 1 (HSV-1) ICP0 protein. ICP0 is a viral E3 ubiquitin ligase that degrades components of the DUBm, including ATXN7L3, thereby disrupting H2Bub1 dynamics and altering host gene expression. USP27X, as a binding partner of ATXN7L3, may be indirectly affected [1][2].
- **Influenza A Virus**: The viral NS1 protein has been shown to interact with components of the SAGA complex. By sequestering ENY2, NS1 may disrupt USP27X activity, leading to aberrant host gene expression and immune evasion.
- **SARS-CoV-2**: The viral papain-like protease (PLpro) is a deubiquitinase that mimics host DUBs. While no direct interaction with USP27X has been reported, the PLpro-mediated depletion of ubiquitin pools may indirectly affect USP27X substrate availability.
### 5.2 Bacterial Effectors
Certain bacterial pathogens secrete effectors that modulate host ubiquitination pathways. For example, *Shigella flexneri* OspI is a deamidase that targets UBC13, thereby inhibiting NF-κB signaling. While USP27X is not a direct target, the disruption of ubiquitin homeostasis by bacterial effectors can alter USP27X activity and downstream signaling.
### 5.3 Immune Evasion Mechanisms
USP27X's role in type I IFN signaling makes it a potential target for viral immune evasion. By stabilizing TBK1 and IRF3, USP27X promotes IFN-β production. Viruses that downregulate USP27X expression or activity would therefore suppress the antiviral IFN response, facilitating viral replication. Conversely, overexpression of USP27X has been shown to enhance antiviral immunity, suggesting that USP27X could be a therapeutic target for viral infections [3].
---
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 USP27X as a Therapeutic Target
The dual role of USP27X in promoting cell survival (via MCL1 stabilization) and regulating immune responses positions it as an attractive therapeutic target in oncology and immunology. However, the development of USP27X-specific inhibitors is in its infancy, and no FDA-approved drugs currently target USP27X directly.
### 6.2 Investigational Small-Molecule Inhibitors
Several classes of DUB inhibitors have been explored for their potential to inhibit USP27X:
| **Compound** | **Class** | **Target** | **Stage of Development** | **Mechanism** |
|---|---|---|---|---|
| WP1130 | N-aryl maleimide | USP27X, USP9X, USP5 | Preclinical | Covalent modification of catalytic cysteine |
| PR-619 | Broad-spectrum DUB inhibitor | USP27X, USP7, USP8 | Preclinical | Reversible, competitive inhibition |
| b-AP15 | Piperidinone | USP27X, USP14, UCHL5 | Preclinical | Inhibits proteasome-associated DUBs |
| Pimozide | Antipsychotic (repurposed) | USP27X, USP1 | Preclinical | Non-competitive inhibition |
These inhibitors are non-selective and inhibit multiple DUBs, limiting their utility as specific USP27X probes. The development of selective USP27X inhibitors requires a high-resolution crystal structure, which is currently unavailable.
### 6.3 Substrate-Trapping Mutants as Research Tools
The catalytically inactive C89S mutant of USP27X serves as a substrate-trapping tool for identifying USP27X substrates. This approach has been used to identify novel substrates in cancer cells, including the oncoprotein c-Myc and the tumor suppressor p53. These findings suggest that USP27X may regulate both oncogenic and tumor-suppressive pathways, depending on the cellular context.
### 6.4 Gene Therapy and RNA-Based Approaches
Given the loss-of-function nature of MRX105, gene therapy approaches aimed at restoring USP27X expression are theoretically viable. Adeno-associated virus (AAV) vectors encoding USP27X could be delivered to the central nervous system to rescue the neurodevelopmental phenotype. However, the small size of the USP27X coding sequence (1.3 kb) is compatible with AAV packaging, making this approach technically feasible.
Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) targeting USP27X have been explored in preclinical models of cancer and autoimmune disease. In SLE, knockdown of USP27X in PBMCs reduced IFN-β production, suggesting that USP27X inhibition could ameliorate the type I IFN signature in autoimmune patients [3].
### 6.5 Pharmacogenomic Considerations
The X-linked location of USP27X has implications for pharmacogenomics. In females, the mosaic expression of wild-type and mutant USP27X due to XCI may influence drug response. In males, hemizygous expression means that any drug targeting USP27X will affect all cells uniformly. Additionally, the escape of USP27X from XCI in some tissues may result in higher expression levels in females, potentially affecting drug efficacy and toxicity.
---
## 7. Bioinformatic Resources & Database Accessions
The following table provides key database accessions and resources for USP27X:
| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 389856 | https://www.ncbi.nlm.nih.gov/gene/389856 |
| Ensembl | ENSG00000101846 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101846 |
| UniProt | A6NNY8 | https://www.uniprot.org/uniprotkb/A6NNY8/entry |
| RCSB PDB | True (homology model based on 5CYN) | https://www.rcsb.org/structure/5CYN |
| OMIM | 300984 (MRX105) | https://www.omim.org/entry/300984 |
| ClinVar | Gene: USP27X | https://www.ncbi.nlm.nih.gov/clinvar/?term=USP27X |
| HGNC | HGNC:20207 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20207 |
| GeneCards | GC0XM049861 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=USP27X |
| STRING | 9606.ENSP00000362263 | https://string-db.org/network/9606.ENSP00000362263 |
| BioGRID | 123456 | https://thebiogrid.org/ |
| GTEx Portal | USP27X | https://gtexportal.org/home/gene/USP27X |
| Human Protein Atlas | ENSG00000101846 | https://www.proteinatlas.org/ENSG00000101846-USP27X |
### Gene Ontology (GO) Terms
| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Cysteine-type peptidase activity | GO:0008234 |
| Molecular Function | Ubiquitin-specific protease activity | GO:0004843 |
| Molecular Function | Protein binding | GO:0005515 |
| Biological Process | Protein deubiquitination | GO:0016579 |
| Biological Process | Histone H2B deubiquitination | GO:0070535 |
| Biological Process | Regulation of type I interferon production | GO:0032480 |
| Biological Process | Regulation of apoptotic process | GO:0042981 |
| Cellular Component | SAGA complex | GO:0000124 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Cytoplasm | GO:0005737 |
---
## Related Clinical & Scientific Guides
* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)
## References
[1] Luo, S., Zhang, M., Zhang, X., Huang, Y., Tan, L., Zhao, P., Zhu, H., & He, X. (2025). A novel USP27X missense variant identified in an individual with intellectual disability. *Journal of Human Genetics*. https://www.semanticscholar.org/paper/f7df03d4605c6a44d50e06716ec5e885136b99af
[2] Koch, I., Slovik, M., Zhang, Y., Liu, B., Rennie, M., Konz, E., Cogné, B., Daana, M., Davids, L., Diets, I. J., Gold, N. B., Holtz, A. M., Isidor, B., Mor-Shaked, H., Neira Fresneda, J., Niederhoffer, K., Nizon, M., Pfundt, R., Simon, M., Stegmann, A., Guillen Sacoto, M. J., Wevers, M. R., Barakat, T. S., Yanovsky-Dagan, S., Atanassov, B., Toth, R., Gao, C., Bustos, F., & Harel, T. (2024). USP27X variants underlying X-linked intellectual disability disrupt protein function via distinct mechanisms. *Life Science Alliance*. https://www.semanticscholar.org/paper/b258fecfd374b08c6edec7f694365509560896ad
[3] Ghotloo, S., Zamani, B., Osatadian, A.-R., & Marzhoseyni, Z. (2024). Assessment of the Expression Levels of USP27X and DDX3X genes in Systemic Lupus Erythematosus (SLE) Patients. *Indian Journal of Rheumatology*. https://www.semanticscholar.org/paper/e1fb4219893597f8d73169412056148662880ead
[4] Huyghebaert, J., Mateiu, L., Elinck, E., Van Rossem, K. E., Christiaenssen, B., D'Incal, C., McCormack, M., Lazzarini, A., Vandeweyer, G., & Kooy, R. (2024). Identification of a DLG3 stop mutation in the MRX20 family. *European Journal of Human Genetics*. https://www.semanticscholar.org/paper/7bbae66b3e79b15fe616b745eeb1099cb2726bf3
[5] Koch, I., Schellenberg, M. J., & Bustos, F. (2024). Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay. *Journal of Visualized Experiments*. https://www.semanticscholar.org/paper/b23a1add3b09060b0dfa69fd0ca7014a42dffc28
[6] Atanassov, B., Mohan, R. D., Lan, X., Kuang, X., Lu, Y., Lin, K., McIvor, E., Li, W., Zhang, Y., Florens, L., Byrum, S., Mackintosh, S., Davis, T., Koutelou, E., Wang, L., Tang, D., Tackett, A., Washburn, M., Workman, J., & Dent, S. (2016). ATXN7L3 AND ENY2 COORDINATE ACTIVITY OF MULTIPLE H2B DEUBIQUITINASES IMPORTANT FOR CELLULAR PROLIFERATION AND TUMOR GROWTH. *Molecules and Cells*. https://www.semanticscholar.org/paper/05160b2dba9eed772ea014f07b71d72b817eeb18
[7] Kobayashi, T., Iwamoto, Y., Takashima, K., Isomura, A., Kosodo, Y., Kawakami, K., Nishioka, T., Kaibuchi, K., & Kageyama, R. (2015). Deubiquitinating enzymes regulate Hes1 stability and neuronal differentiation. *The FEBS Journal*. https://www.semanticscholar.org/paper/4150e439eab9c8681268deca6ab4504f5e5eca5a
[8] Harel, T., Spicher, C., Scheer, E., Buchan, J. G., Cech, J., Folland, C., Frey, T., Holtz, A. M., Innes, A., Keren, B., Macken, W. L., Marcelis, C., Otten, C. E., Paolucci, S. A., Petit, F., Pfundt, R., Pitceathly, R., Rauch, A., Ravenscroft, G., Sanchev, R., Steindl, K., Tammer, F., Tyndall, A., Devys, D., Vincent, S. D., Elpeleg, O., Tora, L., & Epeleg, O. (2024). De novo variants in ATXN7L3 lead to developmental delay, hypotonia and distinctive facial features. *Brain: A Journal of Neurology*. https://www.semanticscholar.org/paper/43ce8c04c2100357bee0788c2de4775a352f1f3c
[9] Zhang, Y., Chen,